Skip to main content
. 2016 Sep 19;17(12):1231–1239. doi: 10.1080/15384047.2016.1235659

Figure 4.

Figure 4.

SS-Fc inhibits tumor growth in vivo. In vivo efficacy studies were performed as described in the Materials and Methods. NOD/SCID mice (n = 5 per group) were engrafted subcutaneously with LS174T cells with or without human PBMCs. (a) Mice were then treated with PBS (solid diamond, PBS treatment, no PBMC transplant); PBMC alone (solid square, PBS treatment, PBMC transplant); SS-Fc (5 μg per mouse, open circle, 20 μg per mouse, open square, with PBMC transplant). Data represent the average tumor volume of 5 mice for each treatment group with error bars representing the standard deviation (** stands for P < 0.01 by t-test, SS-Fc (either 5 μg or 20 per μg mouse) vs. control or PMBC only). (b) Mice were treated with PBS (solid circle, PBS treatment, no NK cell transplant); NK cells alone (solid square, PBS treatment, NK cell transplant); or ss-Fc with NK cells (5 μg per mouse, open circle, NK cell transplant); or ss-Fc only (20 μg per mouse, solid triangle, no NK cell transplant). Data represent the average tumor volume of 7 mice for each treatment group with error bars representing the standard deviation.